Foscarnet
Foscavir (foscarnet) is a small molecule pharmaceutical. Foscarnet was first approved as Foscavir on 1991-09-27. It is used to treat cytomegalovirus infections and herpes genitalis in the USA.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| infections | D007239 |
| urogenital diseases | D000091642 |
Trade Name
FDA
EMA
Foscavir (generic drugs available since 2021-01-29)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Foscarnet sodium
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| FOSCAVIR | CLINIGEN HLTHCARE | N-020068 RX | 1991-09-27 | 1 products, RLD, RS |
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| foscavir | New Drug Application | 2022-08-09 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| cytomegalovirus infections | EFO_0001062 | D003586 | B25 |
| herpes genitalis | EFO_0007282 | D006558 | A60 |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
Code | Description |
|---|---|
| J1455 | Injection, foscarnet sodium, per 1000 mg |
Clinical
Clinical Trials
66 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Venous thromboembolism | D054556 | EFO_0004286 | I74 | 1 | 1 | 4 | 1 | 6 | 12 |
| Pulmonary embolism | D011655 | EFO_0003827 | I26 | 1 | 2 | 2 | 1 | 5 | 10 |
| Thromboembolism | D013923 | HP_0001907 | — | 1 | 6 | 1 | 1 | 9 | |
| Renal insufficiency | D051437 | HP_0000083 | N19 | 1 | — | — | 1 | 1 | 3 |
| Acute coronary syndrome | D054058 | EFO_0005672 | — | — | 1 | 1 | 1 | 3 | |
| Replacement arthroplasty knee | D019645 | — | — | — | 1 | — | 1 | ||
| Thrombocytopenia | D013921 | HP_0001873 | D69.6 | — | — | — | 1 | — | 1 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Venous thrombosis | D020246 | HP_0004936 | I82.40 | 1 | 2 | 6 | — | 7 | 15 |
| Neoplasms | D009369 | C80 | — | — | 1 | — | 1 | 2 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Ovarian neoplasms | D010051 | EFO_0003893 | C56 | 1 | 1 | — | — | — | 2 |
| Respiratory insufficiency | D012131 | HP_0002093 | J96.9 | — | 1 | — | — | — | 1 |
| Embolism and thrombosis | D016769 | — | 1 | — | — | — | 1 | ||
| Viral pneumonia | D011024 | EFO_0007541 | J12.9 | — | 1 | — | — | — | 1 |
| Atrial fibrillation | D001281 | EFO_0000275 | I48.0 | — | 1 | — | — | — | 1 |
| Myocardial infarction | D009203 | EFO_0000612 | I21 | — | 1 | — | — | — | 1 |
| Coronary disease | D003327 | — | 1 | — | — | — | 1 | ||
| Endometrial neoplasms | D016889 | EFO_0004230 | — | 1 | — | — | — | 1 | |
| Sarcoma | D012509 | — | 1 | — | — | — | 1 | ||
| Fallopian tube neoplasms | D005185 | — | 1 | — | — | — | 1 |
Show 3 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Thrombosis | D013927 | 1 | — | — | — | 1 | 2 | ||
| Non-small-cell lung carcinoma | D002289 | 1 | — | — | — | — | 1 | ||
| Morbid obesity | D009767 | EFO_0001074 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Ataxia | D001259 | R27.0 | — | — | — | — | 2 | 2 | |
| Cardiovascular diseases | D002318 | EFO_0000319 | I98 | — | — | — | — | 2 | 2 |
| Covid-19 | D000086382 | U07.1 | — | — | — | — | 1 | 1 | |
| Esophageal neoplasms | D004938 | C15 | — | — | — | — | 1 | 1 | |
| Lung neoplasms | D008175 | C34.90 | — | — | — | — | 1 | 1 | |
| Coronary artery bypass | D001026 | EFO_0003776 | — | — | — | — | 1 | 1 | |
| Kidney diseases | D007674 | EFO_0003086 | N08 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | FOSCARNET |
| INN | foscarnet sodium |
| Description | Phosphonoformic acid is phosphoric acid in which one of the hydroxy groups is replaced by a carboxylic acid group. It is used as the trisodium salt as an antiviral agent in the treatment of cytomegalovirus retinitis (CMV retinitis, an inflamation of the retina that can lead to blindness) and as an alternative to ganciclovir for AIDS patients who require concurrent antiretroviral therapy but are unable to tolerate ganciclovir due to haematological toxicity. It has a role as an antiviral drug, a sodium-dependent Pi-transporter inhibitor, a HIV-1 reverse transcriptase inhibitor and a geroprotector. It is a one-carbon compound, a member of phosphonic acids and a carboxylic acid. It is functionally related to a phosphonic acid and a formic acid. It is a conjugate acid of a phosphonatoformate and a phosphonoformate(2-). |
| Classification | Small molecule |
| Drug class | phosphoro-derivatives |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | O=C(O)P(=O)(O)O |
Identifiers
| PDB | — |
| CAS-ID | 4428-95-9 |
| RxCUI | 33562 |
| ChEMBL ID | CHEMBL666 |
| ChEBI ID | 127780 |
| PubChem CID | 3415 |
| DrugBank | DB00529 |
| UNII ID | 8C5OQ81LWT (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 4,525 documents
View more details
Safety
Black-box Warning
Black-box warning for: Foscavir
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
8,019 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more